Clinical Trials List
2006-01-01 - 2007-06-01
Phase III
Terminated4
ICD-10C64.1
Malignant neoplasm of right kidney, except renal pelvis
ICD-10C64.2
Malignant neoplasm of left kidney, except renal pelvis
ICD-10C64.9
Malignant neoplasm of unspecified kidney, except renal pelvis
ICD-10C7A.093
Malignant carcinoid tumor of the kidney
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9189.0
Malignant neoplasm of kidney, except pelvis
-
Trial Applicant
BAYER TAIWAN COMPANY LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- - - Division of Urology
- Yeong-Shiau Pu Division of Urology
- Yu-Chieh Tsai Division of Hematology & Oncology
- - - Division of Urology
- Chia-Chi Lin Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Jin-Hwang Liu Division of Hematology & Oncology
- Ta-Chung Chao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- See-Tong Pang Division of Urology
- Yung-Chang Lin Division of Hematology & Oncology
- Wen-Cheng Chang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Wu-Chou Su Division of Hematology & Oncology
- 馮盈勳 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
20 participants
-
Global
40 participants
